Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

Home

/

IONS

I

Ionis Pharmaceuticals, Inc. (IONS)

NMS – Цена в реальном времени. Валюта: USD

56.72

+1.30 (2.35%)

Рынок открыт: Aug 12, 2026, 3:08 PM EDT

55.47

+0.05 (0.09%)

Предыдущая сессия: Aug 11, 2026, 7:53 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acquisition increased the director's total direct and indirect equity holdings by 34%.

Видео

No Data

There is no data to display

Пресс-релизы

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

07.08.2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.